What's new? Log in Free sign up

Mesoblast Limited (MESO)

Company Profile

Company profile

Ticker

MESO, MEOBF

Exchange

Website

www.mesoblast.com

CEO

Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Moderna • Bio-Techne • Acorda Therapeutics • Mach Natural Resources ...

Former names

MID AMERICA APARTMENT COMMUNITIES INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

MESO stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Current report (foreign)

Current report (foreign)

Notice of effectiveness

Prospectus supplement

Shelf registration (foreign) (amended)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Shelf registration (foreign)

Current report (foreign)

Transcripts

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

M&G INVESTMENT MANAGEMENT LTD

Financial summary

Financial statements Chart MESO financial data

Quarter (USD)	Jun 24	Jun 23	Jun 22	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jun 24	Jun 23	Jun 22	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

MESO institutional ownership history Ownership history

2.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	44	41	+7.3%
Opened positions	10	16	-37.5%
Closed positions	7	4	+75.0%
Increased positions	13	13	–
Reduced positions	11	3	+266.7%

13F shares	Current	Prev Q	Change
Total value	12.27 bn	9.65 bn	+27.1%
Total shares	33.83 mm	33.77 mm	+0.2%
Total puts	85.70 k	130.00 k	-34.1%
Total calls	340.80 k	250.15 k	+36.2%
Total put/call ratio	0.3	0.5	-51.6%

Largest owners	Shares	Value	Change
George Gregory	32.28 mm	$96.69 mm	0.0%
Group One Trading	253.39 k	$2.07 bn	+11.2%
MS Morgan Stanley	173.60 k	$1.42 bn	+107.6%
Summit X	147.69 k	$1.01 bn	0.0%
Susquehanna International	116.74 k	$953.78 mm	+60.6%
Penbrook Management	107.28 k	$876.44 mm	-14.1%
Prosperity Wealth Management	91.45 k	$747.15 mm	+1.4%
Jane Street	85.10 k	$695.28 mm	+46.4%
BlackRock	81.48 k	$665.68 mm	NEW
Rockbridge Investment Management, LCC	49.15 k	$401.56 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
MS Morgan Stanley	173.60 k	+89.98 k	+107.6%
BlackRock	81.48 k	+81.48 k	NEW
BLK BlackRock	0.00	-70.23 k	EXIT
Marshall Wace	17.72 k	-64.85 k	-78.5%
Chase Investment Counsel	0.00	-59.60 k	EXIT
Susquehanna International	116.74 k	+44.06 k	+60.6%
Citadel Advisors	39.97 k	-37.33 k	-48.3%
XY Capital	29.85 k	+29.85 k	NEW
Jane Street	85.10 k	+26.96 k	+46.4%
WFC Wells Fargo & Company	27.33 k	-25.86 k	-48.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday

This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

Jefferies Downgrades Mesoblast to Hold

US Steel Issues Weak Q4 Outlook, Joins Novo Nordisk And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Press releases

From Benzinga Pro

Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers, with

Mesoblast to be Added to Nasdaq Biotechnology Index

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the Nasdaq

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the United States Food and Drug

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.